Answers are grounded in this paper and cite their sources.
The bradykinin B2 receptor antagonist icatibant has recently become available for treating hereditary angioedema. Our observations demonstrate icatibant to be effective and safe for the treatment of both, abdominal and cutaneous attacks in a practice setting beyond clinical studies.
No takes yet. Share an insight, caveat, or question.
Krause et al. (2009) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: